Literature DB >> 21327569

Growth factors and neuropathic pain.

Michael H Ossipov1.   

Abstract

A treatment for neuropathic pain is an important unmet medical need because this pain often is refractory to many medical interventions. An important element in the development of neuropathic pain is a dysfunction in the activity of peripheral nerves. Because neurotrophic factors affect nerve development and maintenance, modulating the activity of these factors can alter neuronal pathophysiology and produce a disease-modifying effect. Blocking the activity of nerve growth factor or enhancing the activity of either glial-derived neurotrophic factor or artemin has shown potential for normalizing neuronal activity and attenuating signs of neuropathic pain in animal models and clinical studies. This article discusses the role of these factors in neuropathic pain and the implications for the development of novel therapeutics. © Springer Science+Business Media, LLC 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327569     DOI: 10.1007/s11916-011-0183-5

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  58 in total

1.  Postnatal changes in the expression of the trkA high-affinity NGF receptor in primary sensory neurons.

Authors:  D L Bennett; S Averill; D O Clary; J V Priestley; S B McMahon
Journal:  Eur J Neurosci       Date:  1996-10       Impact factor: 3.386

2.  A multiple-dose toxicity study of tanezumab in cynomolgus monkeys.

Authors:  Mark Zorbas; Susan Hurst; David Shelton; Mark Evans; Deborah Finco; Mark Butt
Journal:  Regul Toxicol Pharmacol       Date:  2010-12-03       Impact factor: 3.271

3.  Dorsal root section elicits signs of neuropathic pain rather than reversing them in rats with L5 spinal nerve injury.

Authors:  Sebastian Eschenfelder; Heinz-Joachim Häbler; Wilfrid Jänig
Journal:  Pain       Date:  2000-08       Impact factor: 6.961

4.  Upregulation of bradykinin B2 receptor expression by neurotrophic factors and nerve injury in mouse sensory neurons.

Authors:  Yih-Jing Lee; Olof Zachrisson; David A Tonge; Peter A McNaughton
Journal:  Mol Cell Neurosci       Date:  2002-02       Impact factor: 4.314

5.  Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.

Authors:  J H Kordower; S Palfi; E Y Chen; S Y Ma; T Sendera; E J Cochran; E J Cochran; E J Mufson; R Penn; C G Goetz; C D Comella
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

Review 6.  Nerve growth factor and nociception.

Authors:  G R Lewin; L M Mendell
Journal:  Trends Neurosci       Date:  1993-09       Impact factor: 13.837

7.  Treatment of transected peripheral nerves with artemin improved motor neuron regeneration, but did not reduce nerve injury-induced pain behaviour.

Authors:  Johan Widenfalk; Weiping Wu; Jingxia Hao; Jonas K E Person; Zsuzsanna Wiesenfeldt-Hallin; Mårten Risling
Journal:  Scand J Plast Reconstr Surg Hand Surg       Date:  2009

8.  The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule.

Authors:  S B McMahon; D L Bennett; J V Priestley; D L Shelton
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

9.  Nerve growth factor administration protects against experimental diabetic sensory neuropathy.

Authors:  S C Apfel; J C Arezzo; M Brownlee; H Federoff; J A Kessler
Journal:  Brain Res       Date:  1994-01-14       Impact factor: 3.252

Review 10.  Nerve growth factor and wound healing.

Authors:  Keiko Kawamoto; Hiroshi Matsuda
Journal:  Prog Brain Res       Date:  2004       Impact factor: 2.453

View more
  19 in total

1.  The fundamental unit of pain is the cell.

Authors:  David B Reichling; Paul G Green; Jon D Levine
Journal:  Pain       Date:  2013-12       Impact factor: 6.961

Review 2.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

3.  Treating small fiber neuropathy by topical application of a small molecule modulator of ligand-induced GFRα/RET receptor signaling.

Authors:  Kristian L Hedstrom; Joshua C Murtie; Kathryn Albers; Nigel A Calcutt; Gabriel Corfas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-21       Impact factor: 11.205

4.  Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.

Authors:  Pieter Okkerse; Justin L Hay; Eve Versage; Yongqiang Tang; Gerald Galluppi; Bernard Ravina; Ajay Verma; Leslie Williams; Ernesto Aycardi; Geert Jan Groeneveld
Journal:  Br J Clin Pharmacol       Date:  2016-05-13       Impact factor: 4.335

5.  Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial.

Authors:  Hao Wang; Gary Romano; Mary Ellen Frustaci; Norm Bohidar; Huizhong Ma; Panna Sanga; Seth Ness; Lucille J Russell; Margaret Fedgchin; Kathleen M Kelly; John Thipphawong
Journal:  Neurology       Date:  2014-07-09       Impact factor: 9.910

6.  Recent Developments in Neuropathic Pain Mechanisms: Implications for Treatment.

Authors:  Wahida Rahman; Anthony H Dickenson
Journal:  Rev Pain       Date:  2011-06

Review 7.  Concise review: stem cell therapies for neuropathic pain.

Authors:  Veronica R Fortino; Daniel Pelaez; Herman S Cheung
Journal:  Stem Cells Transl Med       Date:  2013-04-09       Impact factor: 6.940

Review 8.  Regulation of neurotrophin receptor (Trk) signaling: suppressor of cytokine signaling 2 (SOCS2) is a new player.

Authors:  Rachel T Uren; Ann M Turnley
Journal:  Front Mol Neurosci       Date:  2014-05-14       Impact factor: 5.639

Review 9.  Glial Cell Line-Derived Neurotrophic Factor Family Ligands, Players at the Interface of Neuroinflammation and Neuroprotection: Focus Onto the Glia.

Authors:  Anastasiia Kotliarova; Yulia A Sidorova
Journal:  Front Cell Neurosci       Date:  2021-06-17       Impact factor: 5.505

Review 10.  Genomics of pain in osteoarthritis.

Authors:  M Thakur; J M Dawes; S B McMahon
Journal:  Osteoarthritis Cartilage       Date:  2013-09       Impact factor: 6.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.